Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea

BACKGROUND: We investigated the clinical characteristics and treatment outcomes of Korean patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation-positive (EGFRm(+)) non-small cell lung cancer (NSCLC) in a real-world setting. METHODS: Electronic case reports wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sung Yong, Choi, Chang-Min, Chang, Yoon Soo, Lee, Kye Young, Kim, Seung Joon, Yang, Sei Hoon, Ryu, Jeong Seon, Lee, Jeong Eun, Lee, Shin Yup, Park, Ji Young, Kim, Young-Chul, Oh, In-Jae, Jung, Chi Young, Lee, Sang Hoon, Yoon, Seong Hoon, Choi, Juwhan, Jang, Tae Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743522/
https://www.ncbi.nlm.nih.gov/pubmed/35070746
http://dx.doi.org/10.21037/tlcr-21-501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743522/
https://www.ncbi.nlm.nih.gov/pubmed/35070746
http://dx.doi.org/10.21037/tlcr-21-501

Ejemplares similares